Meningococcal Vaccine Industry Research Report 2024

Meningococcal Vaccine Industry Research Report 2024


Summary

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
According to APO Research, the global Meningococcal Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Meningococcal Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Meningococcal Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Meningococcal Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Meningococcal Vaccine include Novartis, GSK, Merck, CSL, Baxter, JN International Medical Corporation, Serum Institute of India, Bio-Med and China National Biotec Group, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Meningococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Vaccine.
The report will help the Meningococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Meningococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (10K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Meningococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Meningococcal Vaccine segment by Type

Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Meningococcal Vaccine segment by Application

6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
Meningococcal Vaccine Segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Meningococcal Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Meningococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Meningococcal Vaccine Market Size (2019-2030) & (US$ Million)
2.2.2 Global Meningococcal Vaccine Sales (2019-2030)
2.2.3 Global Meningococcal Vaccine Market Average Price (2019-2030)
2.3 Meningococcal Vaccine by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
2.3.2 Meningtits A
2.3.3 Polysaccharide Meningtitis AC
2.3.4 Meningitis ACYW
2.4 Meningococcal Vaccine by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 6 Months-15Year
2.4.3 over 3 Year
2.4.4 over 2 Year
2.4.5 over 3 Months
3 Market Competitive Landscape by Manufacturers
3.1 Global Meningococcal Vaccine Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Meningococcal Vaccine Sales (10K Pcs) of Manufacturers (2019-2024)
3.3 Global Meningococcal Vaccine Revenue of Manufacturers (2019-2024)
3.4 Global Meningococcal Vaccine Average Price by Manufacturers (2019-2024)
3.5 Global Meningococcal Vaccine Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Meningococcal Vaccine, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Meningococcal Vaccine, Product Type & Application
3.8 Global Manufacturers of Meningococcal Vaccine, Date of Enter into This Industry
3.9 Global Meningococcal Vaccine Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Novartis
4.1.1 Novartis Company Information
4.1.2 Novartis Business Overview
4.1.3 Novartis Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Novartis Meningococcal Vaccine Product Portfolio
4.1.5 Novartis Recent Developments
4.2 GSK
4.2.1 GSK Company Information
4.2.2 GSK Business Overview
4.2.3 GSK Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.2.4 GSK Meningococcal Vaccine Product Portfolio
4.2.5 GSK Recent Developments
4.3 Merck
4.3.1 Merck Company Information
4.3.2 Merck Business Overview
4.3.3 Merck Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.3.4 Merck Meningococcal Vaccine Product Portfolio
4.3.5 Merck Recent Developments
4.4 CSL
4.4.1 CSL Company Information
4.4.2 CSL Business Overview
4.4.3 CSL Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.4.4 CSL Meningococcal Vaccine Product Portfolio
4.4.5 CSL Recent Developments
4.5 Baxter
4.5.1 Baxter Company Information
4.5.2 Baxter Business Overview
4.5.3 Baxter Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Baxter Meningococcal Vaccine Product Portfolio
4.5.5 Baxter Recent Developments
4.6 JN International Medical Corporation
4.6.1 JN International Medical Corporation Company Information
4.6.2 JN International Medical Corporation Business Overview
4.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.6.4 JN International Medical Corporation Meningococcal Vaccine Product Portfolio
4.6.5 JN International Medical Corporation Recent Developments
4.7 Serum Institute of India
4.7.1 Serum Institute of India Company Information
4.7.2 Serum Institute of India Business Overview
4.7.3 Serum Institute of India Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.7.4 Serum Institute of India Meningococcal Vaccine Product Portfolio
4.7.5 Serum Institute of India Recent Developments
4.8 Bio-Med
4.8.1 Bio-Med Company Information
4.8.2 Bio-Med Business Overview
4.8.3 Bio-Med Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Bio-Med Meningococcal Vaccine Product Portfolio
4.8.5 Bio-Med Recent Developments
4.9 China National Biotec Group
4.9.1 China National Biotec Group Company Information
4.9.2 China National Biotec Group Business Overview
4.9.3 China National Biotec Group Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.9.4 China National Biotec Group Meningococcal Vaccine Product Portfolio
4.9.5 China National Biotec Group Recent Developments
4.10 Hualan Bio
4.10.1 Hualan Bio Company Information
4.10.2 Hualan Bio Business Overview
4.10.3 Hualan Bio Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.10.4 Hualan Bio Meningococcal Vaccine Product Portfolio
4.10.5 Hualan Bio Recent Developments
4.11 Walvax
4.11.1 Walvax Company Information
4.11.2 Walvax Business Overview
4.11.3 Walvax Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.11.4 Walvax Meningococcal Vaccine Product Portfolio
4.11.5 Walvax Recent Developments
4.12 Zhifei
4.12.1 Zhifei Company Information
4.12.2 Zhifei Business Overview
4.12.3 Zhifei Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.12.4 Zhifei Meningococcal Vaccine Product Portfolio
4.12.5 Zhifei Recent Developments
5 Global Meningococcal Vaccine Market Scenario by Region
5.1 Global Meningococcal Vaccine Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Meningococcal Vaccine Sales by Region: 2019-2030
5.2.1 Global Meningococcal Vaccine Sales by Region: 2019-2024
5.2.2 Global Meningococcal Vaccine Sales by Region: 2025-2030
5.3 Global Meningococcal Vaccine Revenue by Region: 2019-2030
5.3.1 Global Meningococcal Vaccine Revenue by Region: 2019-2024
5.3.2 Global Meningococcal Vaccine Revenue by Region: 2025-2030
5.4 North America Meningococcal Vaccine Market Facts & Figures by Country
5.4.1 North America Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Meningococcal Vaccine Sales by Country (2019-2030)
5.4.3 North America Meningococcal Vaccine Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Meningococcal Vaccine Market Facts & Figures by Country
5.5.1 Europe Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Meningococcal Vaccine Sales by Country (2019-2030)
5.5.3 Europe Meningococcal Vaccine Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Meningococcal Vaccine Market Facts & Figures by Country
5.6.1 Asia Pacific Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Meningococcal Vaccine Sales by Country (2019-2030)
5.6.3 Asia Pacific Meningococcal Vaccine Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Meningococcal Vaccine Market Facts & Figures by Country
5.7.1 Latin America Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Meningococcal Vaccine Sales by Country (2019-2030)
5.7.3 Latin America Meningococcal Vaccine Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Meningococcal Vaccine Market Facts & Figures by Country
5.8.1 Middle East and Africa Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Meningococcal Vaccine Sales by Country (2019-2030)
5.8.3 Middle East and Africa Meningococcal Vaccine Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Meningococcal Vaccine Sales by Type (2019-2030)
6.1.1 Global Meningococcal Vaccine Sales by Type (2019-2030) & (10K Pcs)
6.1.2 Global Meningococcal Vaccine Sales Market Share by Type (2019-2030)
6.2 Global Meningococcal Vaccine Revenue by Type (2019-2030)
6.2.1 Global Meningococcal Vaccine Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Meningococcal Vaccine Revenue Market Share by Type (2019-2030)
6.3 Global Meningococcal Vaccine Price by Type (2019-2030)
7 Segment by Application
7.1 Global Meningococcal Vaccine Sales by Application (2019-2030)
7.1.1 Global Meningococcal Vaccine Sales by Application (2019-2030) & (10K Pcs)
7.1.2 Global Meningococcal Vaccine Sales Market Share by Application (2019-2030)
7.2 Global Meningococcal Vaccine Revenue by Application (2019-2030)
7.2.1 Global Meningococcal Vaccine Sales by Application (2019-2030) & (US$ Million)
7.2.2 Global Meningococcal Vaccine Revenue Market Share by Application (2019-2030)
7.3 Global Meningococcal Vaccine Price by Application (2019-2030)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Meningococcal Vaccine Value Chain Analysis
8.1.1 Meningococcal Vaccine Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Meningococcal Vaccine Production Mode & Process
8.2 Meningococcal Vaccine Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Meningococcal Vaccine Distributors
8.2.3 Meningococcal Vaccine Customers
9 Global Meningococcal Vaccine Analyzing Market Dynamics
9.1 Meningococcal Vaccine Industry Trends
9.2 Meningococcal Vaccine Industry Drivers
9.3 Meningococcal Vaccine Industry Opportunities and Challenges
9.4 Meningococcal Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings